40 results about "Urge incontinence" patented technology

Transcutaneous electrical and magnetic nerve stimulation devices are disclosed, along with methods of treating lower urinary tract disorders using energy that is delivered noninvasively by the devices. The disorders comprise overactive bladder, urge incontinence, stress, incontinence, urge frequency, non-obstructive urinary retention and interstitial cystitis / painful bladder syndrome. In preferred embodiments of the disclosed methods, a posterior tibial nerve of a patient is stimulated non-invasively. Methods are disclosed for selecting protocol parameters for a nerve stimulation session for treating each individual patient, wherein modules of the bladder of the patient are represented as coupled non-linear oscillators.

A medical condition is treated using electrical stimulation of contractile tissue, such as a sphineter, as well as electrical stimulation of afferent nerves to illicite a neuron-modulation response. The device (1) and method is particular useful for treating urge incontinence where the tissue is a smooth muscle neo-sphineter (2) about the urethra and the nerves are in the pelvic region.

Apparatus is provided, including an implantable mechanical support, shaped to support a portion of a urethra of a patient. One or more electrodes are coupled to the mechanical support, so as to contact tissue of the patient when the mechanical support is implanted in the patient. A control unit drives the electrodes to apply a current to the tissue. A method for treating a patient is also provided, including implanting a mechanical support in a position that supports a urethra of a patient. In response to increased pelvic pressure of the patient, a substance stored in a portion of the mechanical support that is not under the urethra is moved to a portion of the mechanical support that is under the urethra. Other embodiments are also described.

An apparatus for insertion into a human vagina for treating urinary incontinence, comprising: an intermediate section; an anchoring section located on one side of the intermediate section provided with a plurality of beveled anchoring arms adapted to prevent movement of the apparatus into the vagina; and, a support section located on the opposite side of the intermediate section from the anchoring section provided with a plurality of beveled supporting arms adapted to prevent movement of the apparatus out of the vagina and to provide sub-urethral support.

Apparatus is provided, including an implantable mechanical support comprising a mesh shaped to support a portion of a urethra of a patient. One or more electrodes, coupled to the mesh, so as to contact tissue of the patient when the mechanical support (26) is implanted in the patient. A control unit drives the electrodes to apply a current to the tissue. Other embodiments are also described.

The present invention discloses an implant for placement in the retropubic space of a patient. Novel methods and assemblies for use in conjunction with the implant are also described, which include mechanical positioning of the sling, placement of a mechanical implant underneath the urethra or mechanical vibration (intermittent) under the urethra or other incontinence lumen.

The present invention relates to phenyl or heteroaryl amino alkane derivatives of formula (I) in which the groups Q1-Q4, Ar, and R1-R7 are as defined in the specification and claims. These materials are useful as active ingredients of pharmaceutical preparations. The phenyl or heteroaryl amino alkanes of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with IP receptor antagonistic activity. Such diseases include urological diseases or disorders as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benighn prostatic hypertrophy (BPH), prostatitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity. The compounds of the present invention are also useful for treatment of pain including, but not limited to inflammatory pain, neuropathic pain, acute pain, chronic pain, dental pain, premenstrual pain, visceral pain, headaches, and the like; hypotension; hemophilia and hemorrhage; and inflammation, since these diseases also are alleviated by treatment with an IP receptor antagonist. The application claims the compounds, pharmaceutical compositions containing them, and methods of treatment using them.

Transcutaneous electrical and magnetic nerve stimulation devices and methods generate energy that is delivered noninvasively to selected nerve fibers within the patient to treat lower urinary tract disorders. The disorders comprise overactive bladder, urge incontinence, stress, incontinence, urge frequency, non-obstructive urinary retention and interstitial cystitis / painful bladder syndrome. In preferred embodiments, a posterior tibial nerve of a patient is stimulated non-invasively to treat bladder disorders.

The present invention describes novel nitrosated and / or nitrosylated α-adrenergic receptor antagonists, and novel compositions containing at least one nitrosated and / or nitrosylated α-adrenergic receptor antagonist, and, optionally, one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or are a substrate for nitric oxide synthase, and / or one or more vasoactive agents. The present invention also provides novel compositions containing at least one α-adrenergic receptor antagonist, and one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and / or one or more vasoactive agents. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing benign prostatic hyperplasia, hypertension, congestive heart failure, variant (Printzmetal) angina, glaucoma, neurodegenerative disorders, vasospastic diseases, cognitive disorders, urge incontinence, or overactive bladder, and for reversing the state of anesthesia.

A device (20) for treatment of a patient's urinary incontinence, including a sensor, (44), which generates a signal responsive to a physiological characteristic indicative of a likelihood of incontinence. A control unit (22) receives the signal from the sensor. At least one electrode (29) is preferably implanted in the patient. The electrode is coupled to cause contraction of a pelvic muscle of the patient responsive to application of electrical energy to the electrode. Responsive to the signal, the control unit applies an electrical waveform to the electrode, so as to inhibit the incontinence.

The present invention is directed to the prevention, reversal and medical treatment of lower urinary tract dysfunction including bladder instability and other related diseases as described below including urinary flow problems, urgency and incontinence as a result of prostate hyperplasia (BPH) and to the prevention, reversal and medical treatment of irritable bowl syndrome (IBS) with special focus on the diarrhea-predominant and mixed diarrhea-constipation type IBS, both in human beings and animals.

Described are devices and methods for treating various disorders of the pelvic floor by means of electrical stimulation of the pudendal nerves, and means for delivering one or more drugs in association with such electrical stimulation therapies. One or more electrical stimulation signals are applied, and one or more drugs are infused, injected or otherwise administered, to appropriate portions of a patient's pelvic floor and the pudendal nerves or portions thereof in an amount and manner effective to treat a number of disorders, including, but not limited to, urinary voiding dysfunction, fecal voiding dysfunction, constipation, stress incontinence, urge incontinence, urinary retention disorder, sexual dysfunction, orgasmic dysfunction, erectile dysfunction, pelvic pain, prostatitis, prostatalgia and prostatodynia.

Systems for and methods of assessing lower urinary tract function from urinary flow data via sound analysis and user-provided information regarding the lower urinary tract symptoms (LUTS) of frequency, urgency and urge incontinence. Embodiments of the LUTS assessment systems include a computer and a telephone or a digital recording mechanism to capture the sound of one or more urination events, which are stored as audio files in a database. The LUTS assessment systems may include sound analysis software for analyzing the strength and duration of each urination event and may include a web-based software application for viewing the results via the Internet or other network. The database stores information from multiple urination events, and combined with information regarding the lower urinary tract symptoms, serves as an objective tool to assess bladder function and monitor progression of disease or therapy effectiveness.

The present invention concerns the stimulation of neural tissue, in particular brain tissue for the control of micturition. By activation of the pontine micturition centre (PMC) to induce micturition and deactivation of the pontine micturition centre to inhibit micturition, patients suffering from overactive bladder (OAB) and urge incontinence regain control of the disposal of urine. This treatment will greatly improve these patients' quality of life and helps them to restore their self-confidence.

Discolsed herein are compositions and methods for treatment of genitourinary disorders (e.g., urge incontinence). The compositions may generally include a dual-acting SNRI-NMDA antagonist (e.g., bicifadine and / or milnacipran). Alternatively, the compositions may generally include an SNRI and an NMDA antagonist.

A vapor delivery system and method is provided that is adapted for ablating bladder tissue to treat overactive bladder (OAB). The vapor delivery system includes an anchor tip configured anchor the system in the bladder while condensable vapor is delivered to target tissue. In one method, the vapor delivery system is advanced transurethrally into the patient to access the target tissue of the bladder, which can include a surface sensor of the bladder responsible for creating an urge incontinence sensation. The vapor delivery system includes a vapor source that provides a high quality vapor for delivery to tissue.

Systems for and methods of assessing lower urinary tract function from urinary flow data via sound analysis and user-provided information regarding the lower urinary tract symptoms (LUTS) of frequency, urgency and urge incontinence. Embodiments of the LUTS assessment systems include a computer and a telephone or a digital recording mechanism to capture the sound of one or more urination events, which are stored as audio files in a database. The LUTS assessment systems may include sound analysis software for analyzing the strength and duration of each urination event and may include a web-based software application for viewing the results via the Internet or other network. The database stores information from multiple urination events, and combined with information regarding the lower urinary tract symptoms, serves as an objective tool to assess bladder function and monitor progression of disease or therapy effectiveness.

This invention relates to tetrahydro-naphthalene derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. They have the general formula (I)in which R1 represents hydrogen or C1-6 alkyl, and X represents —N(H)Y1, —(H)—C1-6 alkyleneY1, biphenyl or C1-6 alkyl substituted by biphenyl, and the group Y1 is an optionally substituted biphenyl. The tetrahydro-naphthalene derivatives of the present invention have excellent activity as VR1 antagonists and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, urge urinary incontinence, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.

The present invention is directed to substituted aryl cycloalkanoyl derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

The invention relates to a medicament for rapidly treating urinary retention, which is a traditional herbal preparation prepared from astragalus hoangtchy, behenolin, red fleece-flower root, Cimicifuga foetida, bupleurum, angelica, cortex phellodendr, seed of glabrous leaf pittosporum, nvlei, radix linderae, Japan yam rhizome, Japan Bogorchid, radix achyranthis bidentatae and mole cricket. The medicament especially has obvious curative effect on the old with prostatauxe and acute urinary retention, wherein the effective rate is up to 98 percent and the curative rate is up to 94 percent. The medicament also has efficiency of taking effect after administration, treating diseases rapidly and curing without recurrence on various bowels blocking after surgery, uroschesis due to vesical dysfunction caused by medicament taking, frequent micturition, urgent micturition, urge incontinence, micturition dribble and other disease symptoms, and has the advantages of small dosage, convenient administration and no toxic and side effect.

The invention discloses a bioelectrical impedance based urge incontinence recognition method comprising the following steps of: calculating an electrical impedance signal of the bladder by using a bioelectrical impedance measuring device, carrying out analog-to-digital conversion and digital filtration on the electrical impedance signal, and then, sending the electrical impedance signal to a host computer; carrying out down-sampling treatment on the electrical impedance signal by the host computer by using a time interval prolonging method to obtain data values of a plurality of sampling points, fitting an electrical impedance amplitude curve, and extracting a characteristic parameter of the electrical impedance amplitude curve; and if the host computer judges that the characteristic parameter of the electrical impedance amplitude curve accords with a reference model, judging that a patient has the symptom of urge incontinence by the host computer, and sending an alarm signal. The bioelectrical impedance based urge incontinence recognition method disclosed by the invention can be used for realizing the noninvasive monitoring for the urge incontinence through establishing the reference model for detecting and judging the urge incontinence, and has the advantages of no invasion, on injury, convenience for detection and low cost.

The present invention relates to a phenyl or heteroaryl amino alkane derivatives which are useful as an active ingredient of pharmaceutical preparations. The phenyl or heteroaryl amino alkanes of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with IP receptor antagonistic activity. Such diseases include urological diseases or disorder as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benighn prostatic hypertrophy (BPH), prostatitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity. The compounds of the present invention are also useful for treatment of pain including, but not limited to inflammatory pain, neuropathic pain, acute pain, chronic pain, dental pain, premenstrual pain, visceral pain, headaches, and the like; hypotension; hemophilia and hemorrhage; and inflammation, since the diseases also is alleviated by treatment with an IP receptor antagonist.

The present invention is directed to alkanoyl and cycloalkanoyl-amine derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

This invention relates to tetrahydro-naphthalene derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. They have the general formula (I) in which R1 represents hydrogen or C1-6 alkyl, and X represents —N(H)Y1, —N(H)—C1-6 alkylene Y1, biphenyl or C1-6 alkyl substituted by biphenyl, and the group Y1 is an optionally substituted biphenyl. The tetrahydro-naphthalene derivatives of the present invention have excellent activity as VR1 antagonists and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, urge urinary incontinence, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.

Featured are urodynamic catheters, intravaginal devices, and intrarectal devices, systems and kits thereof, and methods of using the devices, systems, and kits to observe pelvic floor movements in order to monitor bladder function in order to diagnose, treat, or prevent urinary incontinence disorders, such as urge incontinence and stress incontinence.

Featured are intravaginal devices and electrical stimulation devices, systems, thereof, and methods of using the devices and systems thereof to observe pelvic floor movements in order to diagnose, treat, or prevent urinary and fecal incontinence disorders (e.g., urge incontinence) and their accompanying symptoms or to diagnose and / or improve the efficacy of neuromodulation therapy.

The invention relates to the use of a composition comprising an oil-extract and a water-soluble extract, wherein said extracts are obtainable from plant materials and said extracts comprise phytosterols, for the manufacturing of a medicament for the treatment of females suffering from LUTS as a consequence of Interstitial Cystitis and / or stress or urge incontinence.